Is Senolytics safe?

Senolytics are a class of drugs designed to target and eliminate senescent cells, which are cells that have stopped dividing and contribute to aging and age-related diseases. These drugs have shown promise in preclinical studies for extending health span and treating age-related diseases.

Key Insights from Research Papers:

Senolytics have been shown to alleviate disease in numerous organs, improve physical function, and suppress mortality causes in preclinical models, suggesting their potential to extend health span and treat age-related diseases.
Preclinical models indicate that senolytics may be beneficial for treating metabolic dysfunction, type 2 diabetes, and complications arising from diabetes and obesity.
Chronic senolytic treatment has been reported to improve vasomotor function and reduce vascular stiffness in aged or hypercholesterolemic mice, indicating potential cardiovascular benefits.
However, the safety of senolytics like quercetin is questioned, as it may cause cell death in non-senescent endothelial cells at concentrations previously reported to be safe, suggesting a need for more refined senolytic strategies.
Senolytics have been tested in proof-of-concept clinical trials and have shown potential in treating a variety of chronic conditions and age-related diseases, but their safety and efficacy in humans are still under investigation.
Early pilot trials of senolytics suggest they decrease senescent cells and reduce inflammation in humans, but it is too early for senolytics to be used outside of clinical trials until more studies are completed.
Cardiac Glycosides have been identified as having senolytic activity, offering a new potential therapeutic avenue for age-related diseases.
The selectivity of senolytics against senescent cells is modest and cell-type-specific, and while they have shown benefits in animal models, their translation to human therapy requires careful consideration of their paradoxical effects.
Senolytic therapies for Alzheimer's Disease have shown mixed results in human cell models, with some evidence of off-target killing, highlighting the need for more precise senolytic strategies for safe human use.

Conclusion:

Senolytics present a promising avenue for extending health span and treating a range of age-related diseases by targeting senescent cells. While preclinical studies have shown various benefits, including improved physical function and potential cardiovascular improvements, concerns about their safety, particularly regarding off-target effects, remain. The efficacy and safety of senolytics in humans are still under investigation, with early clinical trials suggesting potential benefits but also emphasizing the need for further research to refine these therapies for safe and effective use.

Is Senolytics safe?

Summary

Sources and full results

Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span.

Senolytic drugs, which selectively kill or suppress senescent cells, show potential in alleviating disease, improving physical function, and suppressing mortality in the aged.

Senolytics: Potential for Alleviating Diabetes and Its Complications

Senolytic compounds show promise in treating or preventing obesity-induced metabolic dysfunction, type 2 diabetes, and its complications by targeting cellular senescence.

Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice

Chronic senolytic treatment improves vasomotor function and reduces vascular stiffness in aged and hypercholesterolemic mice, potentially reducing cardiovascular disease morbidity and mortality.

Investigation of quercetin and hyperoside as senolytics in adult human endothelial cells

Quercetin and Q3G are not effective as senolytics for adult human endothelial cells, as they cause cell death in non-senescent cells and have limited therapeutic index.

The Clinical Potential of Senolytic Drugs

Senolytic drugs, which target senescent cells, show potential in preventing and treating multiple age-related diseases and functional deficits.

Senolytic drugs: from discovery to translation

Senolytic drugs selectively clear senescent cells, potentially alleviating over 40 conditions and aging-related dysfunction, in preclinical studies.

Identification and characterization of Cardiac Glycosides as senolytic compounds

Cardiac glycosides show senolytic properties, potentially benefiting age-related diseases by eliminating senescent cells and reducing tumor growth and lung fibrosis.

Paradoxes of senolytics

Senolytics slow aging by killing senescent cells, challenging the theory of aging as a functional decline caused by molecular damage.

Senolytics in a Model of Alzheimer's Disease

Senolytics show potential in Alzheimer's disease models, but more refined strategies are needed for safe human use due to off-target killing.

Discovery, development, and future application of senolytics: theories and predictions

Senolytic drugs, which selectively eliminate senescent cells, show promise in alleviating age-related dysfunction and diseases, with potential applications in multiple disorders.

Try another search